Daniel Rader, MD
Internal Medicine · Philadelphia, PANPI 1316979610
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,634,530 of the $1,668,376 with a category attached, or 98.0%. Alnylam Pharmaceuticals Inc. accounts for 92.7% of it on its own, with 7 other manufacturers making up the rest. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $21,389 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$1.5M
- Pfizer$60K
- Novartis Pharma AG$30K
- AstraZeneca$17K
- Novartis$5K
- CSL Behring$5K
- plus $4K from 2 others
Across 71 payments — averaging $23,184 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$645K
- Sysmex America, Inc.$298K
- CSL Behring$287K
- Biogen$212K
- Pfizer$204K
What the payments were for
- Consulting fees$1,634,53098%
- Speaking & faculty fees$24,0001%
- Travel & lodging$9,1411%
- Food & beverage$7050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 43 | $1,546,960 |
| Pfizer | 9 | $60,442 |
| Novartis Pharma AG | 11 | $29,999 |
| AstraZeneca(2 entities) | 8 | $17,333 |
| Novartis | 3 | $5,486 |
| CSL Behring | 2 | $4,586 |
| Regeneron | 1 | $2,220 |
| Novo Nordisk | 1 | $1,350 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$22,435
- ILARIS$22,435
- LCZ696_ENTRESTO_CARDIOVASCULAR$7,443
- ACZ885M_ILARIS_IMMUNOLOGY$7,443
- RLX030A_INVESTIGATIONAL_CARDIOVASCULAR$7,443
- LIK066X_INVESTIGATIONAL_CARDIOVASCULAR$7,443
- PELACARSEN$3,935
- EVKEEZA$2,220
- LEQVIO$1,550
How this compares
$1,668,376 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- David GoldmannPhiladelphia$525K
- Eyob FeyssaPhiladelphia$328K
- Emil AbramianPhiladelphia$199K
- Michael KnightPhiladelphia$178K
- James BlakePhiladelphia$164K
- Gina SimonciniPhiladelphia$158K
- James LewisPhiladelphia$106K
- David NashPhiladelphia$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.